Large stock option grant to Eikon Therapeutics (EIKN) director and officer

Rhea-AI Filing Summary

PERLMUTTER ROGER M reported acquisition or exercise transactions in this Form 4 filing.

Eikon Therapeutics director and officer Roger M. Perlmutter received a grant of stock options covering 268,176 shares of the company’s stock. The options were awarded at no cash cost on the grant date. According to the vesting terms, 1/48 of the underlying shares vest monthly over 48 months, contingent on his continued service.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PERLMUTTER ROGER M

(Last) (First) (Middle)

C/O EIKON THERAPEUTICS, INC.

230 HARRIET TUBMAN WAY

(Street)

MILLBRAE CA 94030

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Eikon Therapeutics, Inc. [ EIKN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See remarks

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$14.88	03/02/2026		A		268,176		(1)	03/01/2036	Common Stock	268,176	$0	268,176	D

Explanation of Responses:

1. 1/48th of the shares underlying the option will vest on each monthly anniversary of the vesting start date for 48 months, subject to the Reporting Person's continued service through each date.

Remarks:

Chief Executive Officer and Director

	/s/ Benjamin Thorner, Attorney-in-Fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Eikon Therapeutics (EIKN) report on this Form 4?

The Form 4 reports that Roger M. Perlmutter, a director and officer of Eikon Therapeutics, received a grant of stock options. These options give him the right to buy shares of the company’s stock under the specified vesting schedule and terms.

How many Eikon Therapeutics (EIKN) shares are covered by Roger Perlmutter’s stock option grant?

The stock option grant covers 268,176 shares of Eikon Therapeutics common stock. This figure reflects the total number of shares underlying the option that were awarded in this transaction and represents his derivative holdings immediately following the grant.

What is the vesting schedule for Roger Perlmutter’s Eikon Therapeutics (EIKN) stock options?

The options vest over four years, with 1/48 of the underlying shares vesting on each monthly anniversary of the vesting start date. Vesting continues only if Roger Perlmutter remains in service with Eikon Therapeutics through each monthly vesting date.

Does this Eikon Therapeutics (EIKN) Form 4 show a stock purchase or sale in the market?

No, the Form 4 reflects a stock option grant, not an open-market purchase or sale. The transaction is coded as a grant or award acquisition, meaning options were awarded to Roger Perlmutter rather than bought or sold on an exchange.

What was Roger Perlmutter’s Eikon Therapeutics (EIKN) option position after this grant?

After the transaction, Roger Perlmutter held stock options covering 268,176 shares of Eikon Therapeutics common stock. This total equals the number of shares in the reported grant and represents his direct derivative ownership following the award.

Is Roger Perlmutter a director or officer at Eikon Therapeutics (EIKN)?

Roger Perlmutter is both a director and an officer of Eikon Therapeutics. His officer title is referenced in the filing remarks, and his dual role is indicated by the boxes for director and officer being marked on the Form 4 reporting page.